NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

🧠 Let’s Set the Record Straight… Again.
1️⃣ The External Control Arm (ECA) in the $NWBO trial was not based on real-world data, electronic health records, or historical placebo groups.
Instead, it was constructed from patient-level, peer-reviewed data drawn from contemporaneous, randomized controlled trials (RCTs) of standard of care for glioblastoma. That’s precisely what the JAMA Oncology paper states:
“The comparator cohort was constructed from individual patient-level data derived from contemporaneous, randomized, controlled clinical trials.”
📌 Yes, individual patient-level data was used, not summary statistics, not “lego-style dots,” but actual de-identified data shared by academic collaborators. Read the supplementary materials. This is peer-reviewed science, not propaganda.
2️⃣ Innovation Passport (IP) The MHRA did grant one. It’s listed in the UK’s Innovative Licensing and Access Pathway (ILAP) records under the formal designation for Dendritic Cell Vaccines for Glioblastoma, with Northwest Biotherapeutics as sponsor.
It wasn’t “shouted out” because the IP is an intermediate regulatory step, not a marketing point. But it’s absolutely public and verifiable via the MHRA, NICE, and UK Government databases.
3️⃣ Why lie if the story’s so good?
That’s a question for you and your crew. Here’s what’s not being shouted but should be:
✅ DCVax-L showed a median survival of 22.4 months in newly diagnosed GBM, compared to ~15-17 months in RCT controls with a long tail of survivors.
✅ It’s the first Phase 3 glioblastoma trial in decades to report improved overall survival in both newly diagnosed and recurrent settings with no serious safety issues.
✅ It’s now part of MHRA’s new PICV approval framework, designed for personalized cancer vaccines.
And while the stock is manipulated, the data is not.
So let’s reframe your question:
“Why the attacks, the lies, and the desperate FUD if the science wasn’t real?”
Because it is real. And you know it.